Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of subcutaneous CLUSTOID cluster immunotherapy for grass pollen allergic rhinoconjunctivitis
2008-000513-29Phase 3Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Apr 2008
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR) comparing CLUSTOID with Placebo (2 arms). Primary endpoint: Mean total combined score during peak pollen season. Started Apr 2008; status: completed.
02
Drugs
dermatophagoides pteronyssinus extract
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2008-000513-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000513-29.